Efficacy of B Cell Depletion Therapy with Rituximab in Refractory Chronic Recurrent Uveitis Associated with Vogt-Koyanagi-Harada Disease

References

• Yamaki K, Gocho K, Hayakawa K, et al. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol. 2000;165(12):7323–7329. doi:10.4049/jimmunol.165.12.7323.
   PubMed Web of Science ®Google Scholar
• Gocho K, Kondo I, Yamaki K. Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2001;42:2004–2009.
   PubMed Web of Science ®Google Scholar
• Yang P, Ren Y, Li B, et al. Clinical Characteristics of Vogt–Koyanagi–Harada syndrome in Chinese patients. Ophthalmology. 2007;114(3):606–614. doi:10.1016/j.ophtha.2006.07.040.
   PubMed Web of Science ®Google Scholar
• Fang W, Yang P. Vogt-Koyanagi-Harada syndrome. Curr Eye Res. 2008;33(7):517–523. doi:10.1080/02713680802233968.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al Tamimi M, Hemachandran S, et al. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Acta Ophthalmol. 2013;91(6):e486–e493. doi:10.1111/aos.12127.
   PubMed Web of Science ®Google Scholar
• AlBloushi AF, Alfawaz AM, AlZaid A, et al. Incidence, risk factors and surgical outcomes of cataract among patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. Oct 22 2019:1–9. doi:10.1080/09273948.2019.1668430. [Epub ahead of print]).
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, et al. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2012;90(8):e603–e608. doi:10.1111/j.1755-3768.2012.02498.x.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Dosari M, Hemachandran S, et al. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2017;95(1):85–90. doi:10.1111/aos.13189.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al Mudhaiyan T, Al Najashi AA, et al. Chronic recurrent Vogt–Koyanagi–Harada disease and development of ‘sunset glow fundus’ predict worse retinal sensitivity. Ocul Immunol Inflamm. 2017;25(4):475–485. doi:10.3109/09273948.2016.1139730.
   PubMed Web of Science ®Google Scholar
• Fang W, Zhou H, Yang P, et al. Longitudinal quantification of aqueous flare and cells in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2008;92(2):182–185. doi:10.1136/bjo.2007.128967.
   PubMed Web of Science ®Google Scholar
• van Nies JA, Krabben A, Schoones JW, et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systemic literature review. Ann Rheum Dis. 2014;73:861–870.
   PubMed Web of Science ®Google Scholar
• Opdenakker G, Abu El-Asrar AM, Van Damme J. Remnant epitopes generating autoimmunity: from model to useful paradigm. Trends Immunol. 2020;41(5):367–378. doi:10.1016/j.it.2020.03.004.
   PubMed Web of Science ®Google Scholar
• Franks SE, Getahun A, Hogarth PM, et al. Targeting B cells in treatment of autoimmunity. Curr Opin Immunol. 2016;43:39–345. doi:10.1016/j.coi.2016.09.003.
   PubMed Web of Science ®Google Scholar
• Hofmann K, Clauder AK, Manz RA. Targeting B Cells and Plasma Cells in Autoimmune Diseases. Front Immunol. 2018;9:835.
   PubMed Web of Science ®Google Scholar
• Musette P, Bouaziz JD. Front immunol. B Cell modulation strategies in autoimmune diseases: new concepts. Front Immunol. 2018;9:622. doi:10.3389/fimmu.2018.00622.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, et al. The cytokine interleukin-6 and the chemokines CCL20 and CXCL13 are novel biomarkers of specific endogenous uveitic entities. Invest Ophthalmol Vis Sci. 2016;57(11):4606‐4613. doi:10.1167/iovs.16-19758.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, et al. Differential CXC and CX3C chemokine expression profiles in aqueous humor of patients with specific endogenous uveitic entities. Invest Ophthalmol Vis Sci. 2018;59:2222‐2228.
   Web of Science ®Google Scholar
• Legler DF, Loetscher M, Roos RS, et al. B cell–attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med. 1998;187(4):655‐660. doi:10.1084/jem.187.4.655.
   PubMed Web of Science ®Google Scholar
• Marino M, Bartoccioni E, Alboini PE, et al. Rituximab in myasthenia gravis: a “to be or not to be” inhibitor of T cell function. Ann N Y Acad Sci. 2018;1413(1):41–48. doi:10.1111/nyas.13562.
   PubMed Web of Science ®Google Scholar
• Carubbi F, Alunno A, Cipriani P, et al. Rituximab in primary Sjögren’s syndrome: a ten-year journey. Lupus. 2014;23(13):1337–1349. doi:10.1177/0961203314546023.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussanblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Caso F, Rigante D, Vitale A, et al. Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. Clin Rheumatol. 2015;34(10):1817–1820. doi:10.1007/s10067-014-2781-1.
   PubMed Web of Science ®Google Scholar
• Umran RMR, Shukur ZYH. Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease. Mod Rheumatol. 2018;28:197‐199. doi:10.3109/14397595.2015.1071234.
   PubMed Web of Science ®Google Scholar
• Dolz-Marco R, Gallego-Pinazo R, Díaz-Llopis M. Rituximab in refractory Vogt-Koyanagi-Harada disease. J Ophthalmic Inflamm Infect. 2011;1:177‐180. doi:10.1007/s12348-011-0027-9.
   PubMedGoogle Scholar
• Heiligenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 2011;50(8):1390‐1394. doi:10.1093/rheumatology/ker107.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Berchicci L, et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016;100(6):782‐786. doi:10.1136/bjophthalmol-2015-306790.
   PubMed Web of Science ®Google Scholar
• Cornish KS, Kuffova L, Forrester JV. Treatment of diffuse subretinal fibrosis uveitis with rituximab. Br J Ophthalmol. 2015;99:153‐154.
   PubMed Web of Science ®Google Scholar
• Lasave A, You C, Ma L, et al. Long-Term Outcomes Of Rituximab Therapy In Patients With Noninfectious Posterior Uveitis Refractory To Conventional Immunosuppressive Therapy. Retina. 2018;38(2):395‐402. doi:10.1097/IAE.0000000000001563.
   PubMed Web of Science ®Google Scholar
• Inomata H, Sakamoto T. Immunohistochemical studies of Vogt-Koyanagi-Harada disease with sunset sky fundus. Curr Eye Res. 1990;9(sup1):35–40. doi:10.3109/02713689008999417.
   PubMed Web of Science ®Google Scholar
• Chan -C-C, Palestine AG, Kuwabara T, et al. Immunopathologic study of Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1988;105(6):607–611. doi:10.1016/0002-9394(88)90052-9.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Struyf S, Van den Broeck C, et al. Expression of chemokines and gelatinase B in sympathetic ophthalmia. Eye. 2007;21(5):649–657. doi:10.1038/sj.eye.6702342.
   PubMed Web of Science ®Google Scholar
• Shah DN, Piacentini MA, Burnier MN, et al. Inflammatory cellular kinetics in sympathetic ophthalmia a study of 29 traumatized (exciting) eyes. Ocul Immunol Inflamm. 1993;1(3):255–262. doi:10.3109/09273949309085026.
   PubMedGoogle Scholar
• Aziz HA, Flynn HW Jr, Young RC, et al. Sympathetic ophthalmia: clinicopathologic correlation in a consecutive case series. Retina. 2015;35(8):1696–1703. doi:10.1097/IAE.0000000000000506.
   PubMed Web of Science ®Google Scholar
• Dunlop AA, Cree IA, Hague S, et al. Multifocal choroiditis: clinicopathologic correlation. Arch Ophthalmol. 1998;116:801–803.
   PubMedGoogle Scholar
• Lim WK, Chee SP, Sng I, et al. Immunopathology of progressive subretinal fibrosis: a variant of sympathetic ophthalmia. Am J Ophthalmol. 2001;138(3):475–477. doi:10.1016/j.ajo.2004.04.013.
   Google Scholar
• Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, et al. Local cytokine expression profiling in patients with specific autoimmune uveitic entities. Ocul Immunol Inflamm. 2020;28(3):453‐462. doi:10.1080/09273948.2019.1604974.
   Web of Science ®Google Scholar
• Förster R, Mattis AE, Kremmer E, et al. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell. 1996;87(6):1037–1047. doi:10.1016/S0092-8674(00)81798-5.
   PubMed Web of Science ®Google Scholar
• Budmann GA, García Franco L, Pringe A. Long term treatment with infliximab in pediatric Vogt-Koyanagi-Harada disease. Am J Ophthalmol Case Rep. 2018;11:139–141. doi:10.1016/j.ajoc.2018.06.022.
   PubMedGoogle Scholar
• Jeroudi A, Angeles-Han ST, Yeh S. Efficacy of adalimumab for pediatric Vogt-Koyanagi-Harada syndrome. Ophthalmic Surg Lasers Imaging Retina. 2014;45(4):332–334. doi:10.3928/23258160-20140709-09.
   PubMed Web of Science ®Google Scholar
• Flores Robles BJ, Blanco Madrigal J, Sanabria Sanchinel AA, et al. Anti-TNF? therapy and switching in severe uveitis related to Vogt-Koyanagi-Harada syndrome. Eur J Rheumatol. 2017;4(3):226–228. doi:10.5152/eurjrheum.2017.160085.
   PubMedGoogle Scholar
• Takayama K, Obata H, Takeuchi M. Efficacy of adalimumab for chronic Vogt-Koyanagi-Harada disease refractory to conventional corticosteroids and immunosuppressive therapy and complicated by central serous chorioretinopathy. Ocul Immunol Inflamm. 2020;28(3):509–512. doi:10.1080/09273948.2019.1603312.
   PubMed Web of Science ®Google Scholar
• Couto C, Schlaen A, Frick M, et al. Adalimumab Treatment in Patients with Vogt–Koyanagi–Harada Disease. Ocul Immunol Inflamm. 2018;26(3):485–489. doi:10.1080/09273948.2016.1236969.
   PubMed Web of Science ®Google Scholar
• Zmuda M, Tiev KP, Knoeri J, Héron E. Successful use of infliximab therapy in sight-threatening corticosteroid-resistant Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2013;21(4):310–316. doi:10.3109/09273948.2013.775312.
   PubMed Web of Science ®Google Scholar